Isaac Blech - Edge Therapeutics Independent Vice Chairman of the Board

Chairman

Mr. Isaac Blech is Independent Vice Chairman of the Board of Edge Therapeutics, Inc. Mr. Blech has served as Vice Chairman of our board of directors since January 2013. Mr. Blech serves as a director of life sciences companies Cerecor, Inc., a CNS company, a director of ContraFect Corporation, an infectious disease company and a director of Marina Biotech . Mr. Blech serves as Vice Chairman of Diffusion Pharmaceuticals, a company targeting treatment to resistant cancers. Mr. Blech also serves as Vice Chairman of 10 different privately held life sciences companies since 2013.
Age 67
Tenure 11 years
Phone800 208-3343
Webwww.edgetherapeutics.com
Blech earned a B.A. degree from Baruch College in 1975.

Edge Therapeutics Management Efficiency

Edge Therapeutics' management efficiency ratios could be used to measure how well Edge Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 4.17 M in liabilities with Debt to Equity (D/E) ratio of 47.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Edge Therapeutics has a current ratio of 5.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Edge Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Edge Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Edge Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Edge to invest in growth at high rates of return. When we think about Edge Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CHAIRMAN Age

Peter CampEquinix
68
George IIIUniversal
61
Louis CamilleriPhilip Morris International
64
Lucio NotoPhilip Morris International
81
James GormanMorgan Stanley
66
Robert KamfarBluerock Homes Trust
61
George FreemanUniversal
57
Clint GartinMorgan Stanley
N/A
Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey. Edge Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. Edge Therapeutics (EDGE) is traded on NASDAQ Exchange in USA and employs 14 people.

Management Performance

Edge Therapeutics Leadership Team

Elected by the shareholders, the Edge Therapeutics' board of directors comprises two types of representatives: Edge Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edge. The board's role is to monitor Edge Therapeutics' management team and ensure that shareholders' interests are well served. Edge Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edge Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Macdonald, Chief Scientific Officer, Director
Tuija Soanjarvi, Director
Johan Bolin, Vice President Products
Antonio Perna, Co-founder, Business Coordinator Central Italy; Executive Director
KaiOlaf Dammenhain, Partner, Operations Germany
Joerg Kayser, Partner, Operations Germany
Tom Schmitt, Vice President Sales
Albert Marchio, Chief Accounting and Operations Officer
Gabriel Puente, Operations, Mexico/Managing Director of Techedge Mexico
Anders Hove, Independent Director
Vincenzo Perrone, Independent Director
Andrew CPA, CFO
Enrico Negroni, Chairman of the Board
Sabina Catalano, IR Contact Officer
Domenico Restuccia, Founder, CEO, Director
Giuseppe Vargas, Independent Director
Kelly McGurk, Director of Marketing and Communications
Bradford Middlekauff, Senior Vice President General Counsel, Secretary
Goran Appelquist, CTO
Andrew Saik, CFO
Gunilla Ohman, Investor Relations Manager
Florideo Fabrizio, Co-founder, Research & Development
Brian Leuthner, Co-Founder, CEO and President and Director
Erika Giannetti, Partner, Finance/CFO; Executive Director
Gregory Gin, IR Contact Officer
Jonas Hasselberg, Director
Rosemary Crane, Director
James Loughlin, Independent Director
Massimo Compagnoni, Partner, People
Richard Berg, General Counsel
Jose Rodriguez, Co-founder, Managing Partner Iberia & LATAM, Executive Director
Arnd Benninghoff, Director
Roberto Candido, Partner, Industrial & Services Sector Director
Isaac Blech, Independent Vice Chairman of the Board
Herbert DO, Chief Medical Officer
Fermin Carbajales, Partner, Operations Colombia
Daniel Brennan, COO
Pietro Migliavacca, Co-founder, Operations Italy
Eva Garcia, Partner, Sales Spain
Loch Macdonald, Chief Scientific Officer, Director
Andrew Einhorn, CFO
Herbert Faleck, Chief Medical Officer
Sergio Cipolla, Partner, Operations North America/Managing Director of North America
Jose Soares, Operations, Portugal/Managing Director of Techedge Portugal
Kurt Conti, Independent Director
James Healy, Independent Director
Annachiara Svelto, Independent Director
Liam Ratcliffe, Independent Director
Albert II, Chief Accounting and Operations Officer
Karl Thedeen, CEO, Managing Director
Sigrun Hjelmquist, Independent Director
Beatriz Reyero, Independent Director
Sol Barer, Chairman of the Board
Kent Sander, Independent Director
Giorgio Racca, Partner, Business Development; Executive Director
Michael Ruffolo, Independent Chairman of the Board
Andrea Lavazzi, Partner, Energy & Utilities Sector
Alyssa Wyant, Senior Vice President Regulatory Affairs
BengtArne Molin, Vice President - Research & Development
Jose Navarro, Partner, Operations LATAM; Executive Director
Robert Spiegel, Independent Director
Richard Brandon, Chief Marketing Officer
Magnus Larsson, Vice President - Operations

Edge Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edge Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Edge Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edge Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edge Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Parker Hannifin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Parker Hannifin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Parker Hannifin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Parker Hannifin to buy it.
The correlation of Parker Hannifin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Parker Hannifin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Parker-Hannifin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Parker Hannifin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Edge Therapeutics information on this page should be used as a complementary analysis to other Edge Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Consideration for investing in Edge Stock

If you are still planning to invest in Edge Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Edge Therapeutics' history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk